| Texto completo | |
| Autor(es): |
Baptista, Daniela
[1, 2]
;
Bussadori, Karina
[1]
;
Nunes-de-Souza, Ricardo Luiz
[2, 3]
;
Canto-de-Souza, Azair
[1, 2]
Número total de Autores: 4
|
| Afiliação do(s) autor(es): | [1] Univ Fed Sao Carlos, CECH, Dept Psicol, Grp Psicobiol, BR-13565905 Sao Carlos, SP - Brazil
[2] Univ Fed Sao Carlos, UNESP, Programa Posgrad Ciencias Fisiol, BR-13565905 Sao Carlos, SP - Brazil
[3] Sao Paulo State Univ, UNESP, Pharmacol Lab, Sch Pharmaceut Sci, Araraquara, SP - Brazil
Número total de Afiliações: 3
|
| Tipo de documento: | Artigo Científico |
| Fonte: | Brain Research; v. 1294, p. 29-37, OCT 6 2009. |
| Citações Web of Science: | 15 |
| Resumo | |
Intra-amygdala infusion of midazolam, a benzodiazepine receptor agonist, produces anxiolytic-like effects in mice when first exposed to the elevated plus-maze (EPM) and blocks antinociception induced in mice confined in the open arm of the EPM. However, benzodiazepines fail to alter anxiety in maze-experienced rodents, a phenomenon defined as ``one-trial tolerance{''} (OTT). The main purpose of the present study was to investigate whether intra-amygdala midazolam attenuates the open ann-induced antinociception (OAA) in maze-experienced mice. Nociception was assessed by the writhing test (intraperitoneal injection of 0.6% acetic acid). In Experiment 1, nociception was recorded in maze-experienced mice without prior drug treatment. Experiment 2 investigated the effects of systemic midazolam (0.5, 1.0 and 2.0 mg/kg, s.c.), injected before EPM trial 2, on OAA in maze-experienced mice. in Experiment 3, the effects on OAA of intra-amygdala midazolam (30 nmol/0.1 mu l), injected before trial 1 (maze-naive) or before trial 2 (maze-experienced), were observed. The effects on OAA of intra-amygdala midazolam injected before trial 1 and trial 2 were also investigated (Experiment 4). The results showed that OAA remained unchanged in maze-experienced mice and was insensitive to systemic midazolam. However, intra-amygdala midazolam attenuated OAA in maze-naive mice, but not in maze-experienced mice. Even when given before both trial 1 and trial 2, intra-amygdala midazolam failed to alter OAA in maze-experienced mice. Taken together, these results confirm that the GABA(A)/benzodiazepine receptor complex located within the amygdala plays a role in OAA in maze-naive mice. The lack of effects following systemic or intra-amygdala midazolam on OAA in maze-experienced mice suggests that the OTT is also observed in the modulation of nociception and that the GABA(A)/benzodiazepine receptor located within this limbic forebrain structure participates in this process. (C) 2009 Elsevier B.V. All rights reserved. (AU) | |
| Processo FAPESP: | 06/06855-4 - Efeitos da administração sistêmica e intra-amígdala de midazolam na antinocicepção induzida pelo medo em camundongos: influência da reexposição ao labirinto em cruz elevado |
| Beneficiário: | Daniela Baptista de Souza |
| Modalidade de apoio: | Bolsas no Brasil - Iniciação Científica |